SavedAdd your journal

Journals / Journal of Experimental and Clinical Medicine / 2026 / Volume: 38 Issue: 1

The experience of interleukin-1 inhibition in patients with familial Mediterranean fever

Demet Yalçın Kehribar(ONDOKUZ MAYIS ÜNİVERSİTESİ)
Metin Özgen(ONDOKUZ MAYIS ÜNİVERSİTESİ)0000-0002-6842-2918
Pages
—
Publication Date
2021-01-26
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In addition, canakinumab appears to be an alternative treatment option when there is a inconvenience to daily injection or resistance to anakinra treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:This study aimed to present our single-center experience of anakinra and canakinumab treatment in patients with Familial Mediterranean fever (FMF).
📊
Key Findings & Data:This study included 48 patients who were treated with anti-interleukin-1 (antiIL-1) treatment for at least six months.
💡
Conclusion & Impact:In addition, canakinumab appears to be an alternative treatment option when there is a inconvenience to daily injection or resistance to anakinra treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:familial Mediterranean fever · interleukin-1 inhibition · anakinra

Abstract

This study aimed to present our single-center experience of anakinra and canakinumab treatment in patients with Familial Mediterranean fever (FMF). This study included 48 patients who were treated with anti-interleukin-1 (antiIL-1) treatment for at least six months. Initially, all patients with colchicineresistant or intolerant FMF were received anakinra treatment. Then those resistant to anakinra were given canakinumab treatment. Of the 48 (female/male:29/19) patients using anti-IL-1, their age was 31.2 ± 10.7 years, the duration of drug use was 15±8 months. 30 patients were already using anakinra and 18 patients were using canakinumab. Treatment was found to be switched to canakinumab in 9 patients due to non-adherence to daily injection, and inadequate response to anakinra in 9 patients. After the anti-IL-1 treatment the number of attacks, erythrocyte sedimentation rate, C-reactive protein, fibrinogen levels, colchicine dose and proteinuria (for all p<0.001) were decreased. Anti-IL-1 treatment is effective for controlling attacks and reducing proteinuria in patients with colchicine-resistant or intolerant FMF. In addition, canakinumab appears to be an alternative treatment option when there is a inconvenience to daily injection or resistance to anakinra treatment.

🔖

Cite This Article

Kehribar, D. Y., Özgen, M. (2021). The experience of interleukin-1 inhibition in patients with familial Mediterranean fever. Journal of Experimental and Clinical Medicine, Volume: 38 Issue: 1. https://ajindex.com/articles/1423321

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (26)

  1. Abderrazak, A., Syrovets, T., Couchie, D., El Hadri, K., Friguet, B., Simmet, T., Rouis, M., 2015. NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases. Redox Biol. 4, 296–307.
  2. Akar, S., Cetin, P., Kalyoncu, U., Karadag, O., Sari, I., Cınar, M., Yilmaz, S., Onat A.M., Kisacik, B., Erden, A., Balkarli, A., Kucuksahin, O., Oner, S.Y., Senel, S., Tufan, A., Direskeneli, H., Oksuz, F., Pehlivan, Y., Bayindir, O., Keser, G., Aksu, K., Omma, A., Kasifoglu, T., Unal, A.U., Yildiz, F., Balci, M.A., Yavuz, S., Erten, S., Ozgen, M., Sayarlıoglu, M., Dogru, A., Yildirim, G., Oner, F.A., Tezcan, M.E., Pamuk, O.N., Onen, F., 2018. Nationwide Experience with Off-Label Use of Interleukin-1 Targeting Treatment in familial Mediterranean fever Patients. Arthritis Care Res. 70, 1090-4.
  3. Bozkurt, Y., Demir, A., Erman, B., Gul, A., 2015. Unified modeling of familial Mediterranean fever and cryopyrin associated periodic syndromes. Comput Math Methods Med. 2015, 893507.
  4. Cazeneuve, C., Ajrapetyan, H., Papin, S., Roudot-Thoraval, F., Genevieve, D., Mndjoyan, E., Papazian, M., Sarkisian, A., Babloyan, A., Boissier, B., Duquesnoy, P., Kouyoumdjian, J.C., Girodon-Boulandet, E., Grateau, G., Sarkisian, T., Amselem, S., 2000. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. Am j Hum Genet. 67, 1136-43.
  5. Cerquaglia, C., Diaco, M., Nucera, G., La Regina, M., Montalto, M., Manna, R., 2005. Pharmacological and clinical basis of treatment of familial Mediterranean fever (FMF) with colchicine or analogues: an update. Curr Drug Targets Inflamm Allergy. 4, 117-24.
  6. Chae, J.J., Aksentijevich, I., Kastner, D.L., 2009. Advances in the understanding of familial Mediterranean fever and possibilities for targeted treatment. Br J Haematol. 146, 467-78.
  7. Cronstein, B.N., Terkeltaub, R., 2006. The inflammatory process of gout and its treatment. Arthritis Res Ther. 8(Suppl 1), S3.
  8. Franchi, L., Eigenbröd, T., Munoz-Planillo, R., Nurez, G., 2009. The inflammasome; a caspase-1-activation platform that regulates immune response and disease pathogenesis. Nat Immunol. 10, 241-7.
  9. Kucuksahin, O., Yildizgoren, M.T., Ilgen, U., Ates, A., Kinikli, G., Turgay, M., Erten, S., 2017. Anti-interleukin-1 treatment in 26 patients with refractory familial Mediterranean fever. Mod Rheumatol. 27, 350-5.
  10. Nuki, G., 2008. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep. 10, 218-27.
  11. Ozdogan, H., Ugurlu, S., 2017. Canakinumab for the treatment of familial Mediterranean fever. Expert Rev Clin Immunol. 13, 393-404.
  12. Ozen, S., Bilginer, Y., Aktay Ayaz, N., Calguneri, M., 2011. Anti-interleukin treatment for patients with familial Mediterranean fever resistant to colchicine. J.Rheumatol. 38, 516-8.
  13. Ozen, S., Demirkaya, E., Erer, B., Livneh, A., Ben-Chetrit, E., Giancane, G., Ozdogan, H., Abu, I., Gattorno, M., Hawkins, P.N., Yuce, S., Kallinich, T., Bilginer, Y., Kastner, D., Carmona, L., 2016. EULAR recommendation for the management of familial Mediterranean fever. Ann Rheum Dis. 75, 644-51.
  14. Papin, S., Cuenin, S., Agostini, L., Martinon, F., Werner, S., Beer, H.D., Grütter C., Grütter, M., Tschopp, J., 2007. The SPRY domain of pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1 beta processing. Cell Death Differ. 14, 1457-66.
  15. Petrushkin, H., Stanford, M., Fortune, F., Jawad, A.S., 2016. Clinical Review: Familial Mediterranean Fever-An Overview of Pathogenesis, Symptoms, Ocular Manifestations, and Treatment. Ocul Immunol Inflamm. 24, 422-30.
  16. Sari, I., Birlik, M., Kasifoğlu, T., 2014. Familial Mediterranean fever: an updated review. Eur J Rheumatol. 1, 21-33.
  17. Seyahi, E., Ozdogan, H., Celik, S., Ugurlu, S., Yazici, H., 2006. Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents. Clin Exp Rheumatol 24(Suppl 42), 99-103.
  18. Sohar, E., Gafni, J., Pras, M., Heller, H., 1967. Familial Mediterranean fever a survey of 470 cases and review of the literatüre. Am J Med. 43, 227-53.
  19. Soylemezoglu, O., Arga, M., Fidan, K., Gonen, S., Emeksiz, H.C., Hasanoglu, E., Buyan, E., 2010. Unresponsiveness to colchicine treatment in patients with familial Mediterranean fever homozygous for the M694V mutation. J Rheumatol. 37, 182-9.
  20. Stankovic, S.K., Delmas, Y., Torres, P.U., Peltier, J., Pelle, G., Jéru, I., Colombat, M., Grateau, G., 2012. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol Dial Transplant. 27, 1898-901.
  21. TerHaar, N., Lachmann, H., Özen, S., Woo, P., Uziel, Y., Modesto, C., Kone-Paut, I., Cantarini, L., Insalaco, A., Neven, B., Hofer, M., Rigante, D., Al-Mayouf, S., Touitou, I., Gallizzi, R., Papadopoulou-Alataki, E., Martino, S., Kuemmerle-Deschner, J., Obici, L., Iagaru, N., Simon, A., Nielsen, S., Martini, A., Ruperto, N., Gattorno, M., Frenkel, J., 2013. Treatment of autoinflammatory disease: result from the Eurofever Registry and a literatüre review. Ann Rheum Dis. 72, 678-85.
  22. The French FMF Consortium, 1997. A candidate gene for familial Mediterranean fever. Nat Genet. 17, 25-31.
  23. The International FMF Consortium., 1997. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell. 90, 797-807.
  24. Urieli-Shoval, S., Linke, R.P., Matzner, Y., 2000. Expression and function of serum amyloid A, a major acute phase protein, in normal and disease states. Curr Opin Hematol. 7, 64-9.
  25. Van der Hilst, J.C., Simon, A., Drenth, J.P., 2005. Herediaty periodic fever and reactive amyloidosis. Clin Exp Med. 5, 87-98.
  26. Zemer, D., Pras, M., Sohar, E., Modan, M., Cabili, S., Gafni, J., 1986. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N. Engl. J Med. 314, 1001-5.